172 related articles for article (PubMed ID: 18158738)
1. Multiple antigenic peptides as vaccine platform for the induction of humoral responses against dengue-2 virus.
Amexis G; Young NS
Viral Immunol; 2007 Dec; 20(4):657-63. PubMed ID: 18158738
[TBL] [Abstract][Full Text] [Related]
2. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
3. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.
Lauretti F; Chattopadhyay A; de Oliveira França RF; Castro-Jorge L; Rose J; Fonseca BA
Hum Vaccin Immunother; 2016 Sep; 12(9):2327-33. PubMed ID: 27185081
[TBL] [Abstract][Full Text] [Related]
4. High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice.
Zhang ZS; Yan YS; Weng YW; Huang HL; Li SQ; He S; Zhang JM
J Virol Methods; 2007 Aug; 143(2):125-31. PubMed ID: 17532481
[TBL] [Abstract][Full Text] [Related]
5. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
Arora U; Tyagi P; Swaminathan S; Khanna N
Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
[TBL] [Abstract][Full Text] [Related]
6. Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses.
Li S; Peng L; Zhao W; Zhong H; Zhang F; Yan Z; Cao H
Vaccine; 2011 May; 29(20):3695-702. PubMed ID: 21419774
[TBL] [Abstract][Full Text] [Related]
7. Antibody responses to an immunodominant nonstructural 1 synthetic peptide in patients with dengue fever and dengue hemorrhagic fever.
Huang JH; Wey JJ; Sun YC; Chin C; Chien LJ; Wu YC
J Med Virol; 1999 Jan; 57(1):1-8. PubMed ID: 9890415
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys.
Liu G; Song L; Beasley DW; Putnak R; Parent J; Misczak J; Li H; Reiserova L; Liu X; Tian H; Liu W; Labonte D; Duan L; Kim Y; Travalent L; Wigington D; Weaver B; Tussey L
Clin Vaccine Immunol; 2015 May; 22(5):516-25. PubMed ID: 25761459
[TBL] [Abstract][Full Text] [Related]
9. Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2.
Izquierdo A; Valdés I; Gil L; Hermida L; Gutiérrez S; García A; Bernardo L; Pavón A; Guillén G; Guzmán MG
Antiviral Res; 2012 Jul; 95(1):1-8. PubMed ID: 22554934
[TBL] [Abstract][Full Text] [Related]
10. Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen.
Sim AC; Lin W; Tan GK; Sim MS; Chow VT; Alonso S
Vaccine; 2008 Feb; 26(9):1145-54. PubMed ID: 18243432
[TBL] [Abstract][Full Text] [Related]
11. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
Khanam S; Pilankatta R; Khanna N; Swaminathan S
Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
[TBL] [Abstract][Full Text] [Related]
12. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein.
Mota J; Acosta M; Argotte R; Figueroa R; Méndez A; Ramos C
Vaccine; 2005 May; 23(26):3469-76. PubMed ID: 15837370
[TBL] [Abstract][Full Text] [Related]
13. Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine.
Simmons M; Murphy GS; Hayes CG
Am J Trop Med Hyg; 2001 Aug; 65(2):159-61. PubMed ID: 11508393
[TBL] [Abstract][Full Text] [Related]
14. A novel immunization approach for dengue infection based on conserved T cell epitopes formulated in calcium phosphate nanoparticles.
Huang X; Karabudak A; Comber JD; Philip M; Morcol T; Philip R
Hum Vaccin Immunother; 2017 Nov; 13(11):2612-2625. PubMed ID: 28933657
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical development of a dengue recombinant subunit vaccine.
Manoff SB; George SL; Bett AJ; Yelmene ML; Dhanasekaran G; Eggemeyer L; Sausser ML; Dubey SA; Casimiro DR; Clements DE; Martyak T; Pai V; Parks DE; Coller BA
Vaccine; 2015 Dec; 33(50):7126-34. PubMed ID: 26458804
[TBL] [Abstract][Full Text] [Related]
16. Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates.
Govindarajan D; Meschino S; Guan L; Clements DE; ter Meulen JH; Casimiro DR; Coller BA; Bett AJ
Vaccine; 2015 Aug; 33(33):4105-16. PubMed ID: 26144900
[TBL] [Abstract][Full Text] [Related]
17. Identification of a dengue virus type 2 (DEN-2) serotype-specific B-cell epitope and detection of DEN-2-immunized animal serum samples using an epitope-based peptide antigen.
Wu HC; Jung MY; Chiu CY; Chao TT; Lai SC; Jan JT; Shaio MF
J Gen Virol; 2003 Oct; 84(Pt 10):2771-2779. PubMed ID: 13679612
[TBL] [Abstract][Full Text] [Related]
18. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.
Coller BA; Clements DE; Bett AJ; Sagar SL; Ter Meulen JH
Vaccine; 2011 Sep; 29(42):7267-75. PubMed ID: 21777637
[TBL] [Abstract][Full Text] [Related]
19. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes.
Etemad B; Batra G; Raut R; Dahiya S; Khanam S; Swaminathan S; Khanna N
Am J Trop Med Hyg; 2008 Sep; 79(3):353-63. PubMed ID: 18784226
[TBL] [Abstract][Full Text] [Related]
20. Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine.
Simmons M; Murphy GS; Kochel T; Raviprakash K; Hayes CG
Am J Trop Med Hyg; 2001 Nov; 65(5):420-6. PubMed ID: 11716093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
